NEEDHAM, Mass.--(BUSINESS WIRE)--Sept. 14, 2006--As the biopharma industry is transforming itself from empirical trial-and-error experimentation to an industry reliant upon information, computation and prediction of outcomes, a plethora of post-genomic technologies -- including high-throughput genotyping, microarray analysis, systems biology, proteomics and metabolic profiling - is providing the informational foundation for sophisticated computational and informatics approaches to gather, interpret, and analyze biological, chemical, and clinical data.
